FOUR locally developed Covid-19 vaccines are now being tried out on humans, deputy government spokesperson Ratchada Dhnadirek said.
She added that a budget of 4.8 billion baht (RM607.5mil) has been earmarked for the research and development of these vaccines.
The status of the four vaccines is as follows:
> NDV-HXP-S – This vaccine developed by the Government Pharmaceutical Organisation in collaboration with Mahidol University entered the second phase of trials on humans on Aug 16 and results can be expected in December. The project is set to seek funding for third-phase trials.
> Chula-Cov19 – Developed by Chulalongkorn University’s Vaccine Research Centre, this vaccine entered second-phase trials on humans in August and results can be expected in December.
> Baiya SARS-CoV-2 Vax – This vaccine, developed by Chulalongkorn University start-up Baiya Phytopharm, entered the first phase of trials on humans in October.
> Covigen – Developed by BioNet-Asia, this vaccine entered the first phase of trials on humans on June 25.
“Prime Minister Prayut Chan-o-cha is paying close attention to Covid-19 vaccine projects and is ready to allocate funds to support research and development, efficiency tests and registration, in a bid to maintain Thailand’s vaccine stability,” Ratchada said on Saturday. — The Nation/ANN